Acerca de
Laboratoire de recherche du vieillissement. Drug discovery, biomarkers, cellular reprogramming, aging biology.
Sede
San Francisco, California, USA
Fundada
2013
Tipo
Laboratorio
Ecosistemas
1
Identidad jurídica
- Nombre jurídico
- Calico Life Sciences LLC
- Estado
- Activo
- Verificado el
- 2026-08-30
- Próxima revisión
- 2026-11-30
Misión
“Harness advanced technologies to increase human healthspan.”
Áreas de enfoque
Aging biologyDrug discoverySenolyticsCellular reprogrammingBiomarkers
Participación en ecosistemas
Hoja de ruta estratégica
2025 Q4
● En cursoABBV-CLS-628 enters Phase 2 for ADPKD
Calico reported on 2 October 2025 that its anti-PAPP-A monoclonal antibody had received FDA Fast Track designation and was enrolling an ongoing Phase 2 trial for autosomal dominant polycystic kidney disease. It is not described as a senolytic.
Longevidad y Antienvejecimiento
2026 Q4
◯ PlanificadoCombination therapy trials initiate
Multiple senolytic agents + reprogramming regimen.
Longevidad y Antienvejecimiento
2028 Q2
◯ PlanificadoAge reversal demonstrated 5+ years
Biomarker validation. Aging reversal in humans.
Longevidad y Antienvejecimiento